Module

Novel Therapeutic Approaches

Source: Research Priorities in Non-Small-Cell Lung Cancer

Novel Therapeutic Approaches

Faculty:
Roy S. Herbst, MD, PhD

CME CREDIT INFORMATION

Release Date: 03/07/07

Expiration Date: 03/06/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.0 contact hour (0.1 CEUs)

Registered Nurses: 0.9 Nursing CE credit

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the use of epidermal growth factor inhibitors in the setting of NSCLC
Discuss clinical data regarding the use of bevacizumab in NSCLC
Summarize the use of kinase inhibitors in patients with lung cancer

Topics covered include:

Introduction
Epidermal Growth Factor Receptor Inhibitors
Antiangiogenic Agents
Multikinase Inhibitors
PI3K-Akt-mTOR Pathway
Trial Design Issues
Conclusion
Priority Issues in Novel Therapies
References
Appendix A: Schema for Current and Proposed Clinical Trials

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.